# Ashwagandha clinical safety studies

> Live situation record from CLSTR: https://clstr.news/situations/ashwagandha-clinical-safety-studies
> Updated: 2026-10-22T15:22:19.000Z. Sources: 3. Developments: 2.

A large-scale, multicentre, randomized, double-blind, placebo-controlled clinical trial conducted in India has reported that daily administration of a standardized Ashwagandha root extract is well tolerated over a 24-week period. The study, involving 1,200 healthy adults, found no evidence of treatment-related hepatic or renal injury, with liver enzymes and creatinine levels remaining within normal reference ranges.

These findings, published in Frontiers in Medicine, contrast with reports from some physicians regarding severe liver damage and fatalities linked to the supplement. While the study indicates safety, regulatory stances vary internationally; for example, Denmark has banned its sale in dietary supplements, and the German Federal Institute for Risk Assessment has advised against its consumption for two years.

## Claims

- A study of 1,200 healthy adults found no evidence of liver or kidney damage from Ashwagandha. (corroborated by 3 sources)
- The study was led by Dr. Arvind Chopra from the Centre for Rheumatic Diseases in Pune. (corroborated by 3 sources)
- Denmark has banned the sale of Ashwagandha in dietary supplements. (corroborated by 3 sources)
- The German Federal Institute for Risk Assessment has advised against taking Ashwagandha for two years. (corroborated by 3 sources)
- Some doctors have reported severe liver damage and deaths associated with Ashwagandha. (corroborated by 3 sources)

## Timeline

### 2026-10-22: Ashwagandha study finds no liver or kidney damage

A major Indian study of 1,200 participants found no evidence of liver or kidney damage from Ashwagandha, despite conflicting medical reports and regulatory restrictions in countries like Denmark.

3 sources. https://clstr.news/cluster/ashwagandha-study-finds-no-liver-or-kidney-damage

### 2026-09-28: Ashwagandha clinical trial shows safety over 24 weeks

A large clinical trial in India found that 24 weeks of daily standardised Ashwagandha root extract is well tolerated, with no evidence of liver or kidney injury among 1,200 participants.

2 sources. https://clstr.news/cluster/ashwagandha-clinical-trial-shows-safety-over-24-weeks

---
Cite as: Ashwagandha clinical safety studies. CLSTR, https://clstr.news/situations/ashwagandha-clinical-safety-studies